Richard Lim
Founder bei Cure Ventures Management LP
Profil
Richard J.
Lim is the founder of Cure Ventures Management LP, which was founded in 2021.
He is currently a Managing Partner at Cure Ventures Management LP.
Mr. Lim's current jobs include being a Managing Director at Omega Fund Management LLC since 2008, a Director & Managing Partner at Xenimmune Therapeutics, Inc., a Catalyst Advisory at Massachusetts Institute of Technology, and a Member-Executive Board at Danish BioVenture General Partner ApS.
Mr. Lim's former jobs include being a Director at Spherics, Inc., HydroCision, Inc., and Trident Pharmaceuticals, Inc. He was also an Independent Director at Paratek Pharmaceuticals, Inc. from 2014 to 2018, a Director at Gossamer Bio, Inc. in 2018, a Director at Nuvation Bio Operating Co., Inc., a Vice President at Saunders Karp & Megrue Partners LLC, and a Manager at The Lek.
Additionally, Mr. Lim was a General Partner at MVM Partners LLP from 2002 to 2008 and an Associate at Wolfensohn & Co., Inc. Mr. Lim's education includes an undergraduate degree from Harvard University in 1993 and an MBA from Harvard Business School in 1998.
Aktive Positionen von Richard Lim
| Unternehmen | Position | Beginn |
|---|---|---|
Danish BioVenture General Partner ApS
 Danish BioVenture General Partner ApS Financial ConglomeratesFinance Danish BioVenture General Partner ApS operates as a general partner and renders investment advice to K/S Danish BioVenture. It manages the administration and acts as a representative of Danish BioVenture in external commercial relations. The company was founded on June 26, 2009 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Omega Fund Management LLC
 Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | President | 01.01.2008 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Cure Ventures Management LP
 Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Founder | 01.07.2021 |
Xenimmune Therapeutics, Inc.
 Xenimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xenimmune Therapeutics, Inc. develops antibody-enzyme fusion to target tumors and trigger the hyper-acute rejection. The private company is located in the US. | Director/Board Member | - |
Ehemalige bekannte Positionen von Richard Lim
| Unternehmen | Position | Ende |
|---|---|---|
| GOSSAMER BIO, INC. | Director/Board Member | 19.12.2018 |
| PARATEK PHARMACEUTICALS, INC. | Director/Board Member | 11.04.2018 |
Spherics, Inc.
 Spherics, Inc. Pharmaceuticals: MajorHealth Technology Spherics, Inc. develops pharmaceutical products to address the clinical needs of neurological disorders. Its technology is based on proprietary bio adhesive, biodegradable polymers, enhancers, and coatings. The company has established two distinct drug delivery systems: nano and macro spheres. Spherics was founded by Dr. Edith Mathiowitz in 1997 and is located in Mansfield, MA. | Director/Board Member | 07.01.2010 |
MVM Partners LLP
 MVM Partners LLP Investment ManagersFinance MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01.01.2008 |
| ░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Ausbildung von Richard Lim
| Harvard University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| Private Unternehmen | 12 |
|---|---|
Spherics, Inc.
Spherics, Inc. Pharmaceuticals: MajorHealth Technology Spherics, Inc. develops pharmaceutical products to address the clinical needs of neurological disorders. Its technology is based on proprietary bio adhesive, biodegradable polymers, enhancers, and coatings. The company has established two distinct drug delivery systems: nano and macro spheres. Spherics was founded by Dr. Edith Mathiowitz in 1997 and is located in Mansfield, MA. | Health Technology |
HydroCision, Inc.
 HydroCision, Inc. Medical SpecialtiesHealth Technology HydroCision, Inc. develops, manufactures and markets fluid-jet based surgical tools. Its products include spinejet system, spinejet XL, hydrodiscectomy system and allograft system. The company was founded by Kevin P. Staid and Timothy E. Moutafis in 1994 and is headquartered in North Billerica, MA. | Health Technology |
Trident Pharmaceuticals, Inc.
 Trident Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Trident Pharmaceuticals, Inc. develops novel biologics for the treatment of autoimmune disorders. The company was founded by Charles M. Cohen and Robin Brown in March 2006 and is headquartered in Boston, MA. | Health Technology |
Saunders Karp & Megrue Partners LLC
 Saunders Karp & Megrue Partners LLC Financial ConglomeratesFinance Saunders Karp & Megrue (SKM) is a private merchant bank located in New York City. The firm is a subsidiary of Apax Partners, Inc., itself a subsidiary of Apax Partners Worldwide LLP. | Finance |
The Lek/Alcar Consulting Group, Inc.
 The Lek/Alcar Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA. | Commercial Services |
MVM Partners LLP
MVM Partners LLP Investment ManagersFinance MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom. | Finance |
| Wolfensohn & Co., Inc. | Finance |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US. | Finance |
Danish BioVenture General Partner ApS
Danish BioVenture General Partner ApS Financial ConglomeratesFinance Danish BioVenture General Partner ApS operates as a general partner and renders investment advice to K/S Danish BioVenture. It manages the administration and acts as a representative of Danish BioVenture in external commercial relations. The company was founded on June 26, 2009 and is headquartered in Copenhagen, Denmark. | Finance |
Nuvation Bio Operating Co., Inc.
 Nuvation Bio Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY. | Health Technology |
Cure Ventures Management LP
Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Finance |
Xenimmune Therapeutics, Inc.
Xenimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xenimmune Therapeutics, Inc. develops antibody-enzyme fusion to target tumors and trigger the hyper-acute rejection. The private company is located in the US. | Health Technology |
